Search for:
Author

Prof. Dr. Christian Burholt LL.M.

Browsing
Prof. Dr. Christian Burholt is a partner in the Firm's Berlin office. He has more than 18 years of experience representing German and international clients in antitrust, leniency, dominance, and merger control law matters. In addition, he is Head of the Firm's German Healthcare & Life Sciences Industry Group and member of the EMEA Healthcare & Life Sciences Steering Committee. Christian has been consistently recommended in various legal directories, including JUVE, Handelsblatt/Best Lawyers in Germany, Legal 500, Expert Guides Life Sciences and Who’s Who Legal, for his antitrust, merger control, pharma, medtech and healthcare work. Christian is admitted to the Berlin bar and a member of the German Association of Antitrust Lawyers and the Network Compliance. He is an honorary professor for antitrust law at the Berlin School of Economics and Law (Hochschule für Wirtschaft und Recht Berlin) and regularly lectures and publishes on antitrust and merger control topics.

On 8 July 2022, the German Health Ministry officially shared the second edition of a new bill referred to as the Act for Financial Stability of the Public Health Insurance (GKV-Finanzstabilisierungsgesetz). The bill is still subject to discussions with stakeholders and several rounds of congress hearings. If ultimately implemented, which is a likely scenario, pharma companies will face several painful cutbacks on the statutory reimbursement of prescription-only medicinal products.

In this event, we will give you a comprehensive overview of the most important developments of the last year in German and European antitrust law. Please note that this event will be held in German only.